Yuguo Chen
Jinan, Shandong, 250012, China
Completed
NCT Number: NCT05550805
Prognostic Study of Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease Based on Metabolomics, and Lipidomics (BIPass II)
To investigate whether there were differences in metabolomics and lipidomics in patients with coronary artery disease who had major adverse cardiovascular events during follow-up compared with those who did not.
Completed
Looking for future studies?
Notify MeKey information
Age range
18 year and older
Sex eligibility
All sexes
Study type
Observational
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Hospitalized patients with the diagnosis of any type of coronary artery disease;
- Age ≥18 years of age;
- Patient or guardian provided informed written consent.
Exclusion criteria
- Prior surgery, trauma or clinically evident coagulopathic bleeding within the previous 2 weeks;
- Bipass population with missing follow-up records in Qilu Hospital emergency follow-up cohort.
Treatment and study plan
Primary outcomes
-
major adverse cardiovascular events
Time frame: 20191101-20220701
cardiac death, myocardial infarction, heart failure, stroke
Sponsors and collaborators
Lead sponsor
Qilu Hospital of Shandong University
Other
Registry information
Official study title
Prognostic Study of Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease Based on Metabolomics, and Lipidomics
Important dates
- Study start
- 2017
- Primary completion
- 2022
- Study completion
- 2022
- First posted
- Sep 22, 2022
- Registry last updated
- May 31, 2025
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.